Inogen Valuation Multiples

Discover Inogen's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Apyx Medical, Deltex Medical Group, NN, Ilex Medical and more.

Inogen Overview

About Inogen

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.


Founded

2001

HQ

United States

Employees

766

Website

inogen.com

Financials (LTM)

Revenue: $359M
EBITDA: $3M

EV

$84M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Inogen Financials

Inogen reported last 12-month revenue of $359M and EBITDA of $3M.

In the same LTM period, Inogen generated $160M in gross profit, $3M in EBITDA, and had net loss of ($22M).

Revenue (LTM)


Inogen P&L

In the most recent fiscal year, Inogen reported revenue of $349M and EBITDA of $3M.

Inogen is unprofitable as of last fiscal year, with gross margin of 44%, EBITDA margin of 1%, and net margin of (7%).

See analyst estimates for Inogen
LTMLast FY202320242025202620272028
Revenue$359M$349M$316M$336M$349M
Gross Profit$160M$154M$127M$155M$154M
Gross Margin45%44%40%46%44%
EBITDA$3M$3M($58M)($22M)($10M)
EBITDA Margin1%1%(18%)(6%)(3%)
EBIT Margin(8%)(9%)(24%)(13%)(9%)
Net Profit($22M)($23M)($102M)($36M)($23M)
Net Margin(6%)(7%)(32%)(11%)(7%)

Financial data powered by Morningstar, Inc.

Inogen Stock Performance

Inogen has current market cap of $177M, and enterprise value of $84M.

Market Cap Evolution


Inogen's stock price is $6.54.

Inogen share price increased by 1.4% in the last 30 days, and by 3.6% in the last year.

Inogen has an EPS (earnings per share) of $-0.84.

See more trading valuation data for Inogen
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$84M$177M0.0%1.4%-8.0%3.6%$-0.84

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Inogen Valuation Multiples

Inogen trades at 0.2x EV/Revenue multiple, and 29.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Inogen

EV / Revenue (LTM)


Inogen Financial Valuation Multiples

As of July 10, 2026, Inogen has market cap of $177M and EV of $84M.

Inogen has a P/E ratio of (8.0x).

LTMLast FY202320242025202620272028
EV/Revenue0.2x0.2x0.3x0.2x0.2x
EV/EBITDA29.0x31.1x(1.4x)(3.9x)(8.8x)
EV/EBIT(3.0x)(2.8x)(1.1x)(2.0x)(2.8x)
EV/Gross Profit0.5x0.5x0.7x0.5x0.5x
P/E(8.0x)(7.8x)(1.7x)(4.9x)(7.8x)
EV/FCF(4.4x)(3.9x)(2.8x)(7.5x)(3.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Inogen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Inogen Margins & Growth Rates

Inogen grew revenue by 6% and EBITDA by 14% in the last fiscal year.

In the most recent fiscal year, Inogen reported gross margin of 44%, EBITDA margin of 1%, and net margin of (7%).

See estimated margins and future growth rates for Inogen

Inogen Margins

Last FY202420252026202720282029
Gross Margin44%46%44%45%
EBITDA Margin1%(6%)(3%)1%
EBIT Margin(9%)(13%)(9%)(7%)
Net Margin(7%)(11%)(7%)(6%)
FCF Margin(6%)(3%)(6%)(1%)

Inogen Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%6%4%6%
Gross Profit Growth7%22%(0%)7%
EBITDA Growth14%(63%)(56%)(132%)
EBIT Growth(12%)(44%)(29%)(12%)
Net Profit Growth(5%)(65%)(37%)(5%)
FCF Growth(75%)(63%)93%(75%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Inogen Operational KPIs

Inogen's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Inogen's Rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Inogen's Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Inogen
LTMLast FY202320242025202620272028
Rule of 408%7%---
Bessemer Rule of X18%16%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue28%28%34%31%28%
G&A Expenses to Revenue19%19%24%22%19%
R&D Expenses to Revenue6%6%7%6%6%
Opex to Revenue-53%64%59%53%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Inogen Competitors

Inogen competitors include Apyx Medical, Deltex Medical Group, NN, Ilex Medical, Viromed Medical, Lucid Diagnostics, Pro-Dex, Quanterix, Nyxoah and Surgical Science.

Most Inogen public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Apyx Medical3.5x3.3x(48.8x)(47.1x)
Deltex Medical Group----
NN0.9x0.9x7.9x7.4x
Ilex Medical0.4x-3.1x-
Viromed Medical28.1x6.3x102.4x45.7x
Lucid Diagnostics41.2x31.8x(3.4x)(3.8x)
Pro-Dex2.9x2.6x13.9x13.7x
Quanterix0.9x0.8x(2.8x)(4.6x)

This data is available for Pro users. Sign up to see all Inogen competitors and their valuation data.

Start Free Trial

Acquisitions by Inogen

Inogen has acquired 1 company to date.

Last acquisition by Inogen was on July 13th 2023. Inogen acquired PhysioAssist for $32M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Inogen

PhysioAssist
Description
Physio-Assist is a French developer of airway clearance devices at the intersection of materials physics, signal processing, and life sciences. Founded in 2012 and based in Normandy, the company optimizes products for daily use by healthcare professionals to improve patient respiratory therapy outcomes.
HQ CountryFrance
HQ City
Aix-en-Provence
Deal Date13 Jul 2023
Valuation$32M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Inogen acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Inogen

When was Inogen founded?Inogen was founded in 2001.
Where is Inogen headquartered?Inogen is headquartered in United States.
How many employees does Inogen have?As of today, Inogen has over 766 employees.
Who is the CEO of Inogen?Inogen's CEO is Kevin R. M. Smith.
Is Inogen publicly listed?Yes, Inogen is a public company listed on Nasdaq.
What is the stock symbol of Inogen?Inogen trades under INGN ticker.
When did Inogen go public?Inogen went public in 2014.
Who are competitors of Inogen?Inogen main competitors include Apyx Medical, Deltex Medical Group, NN, Ilex Medical, Viromed Medical, Lucid Diagnostics, Pro-Dex, Quanterix, Nyxoah, Surgical Science.
What is the current market cap of Inogen?Inogen's current market cap is $177M.
What is the current revenue of Inogen?Inogen's last 12 months revenue is $359M.
What is the current revenue growth of Inogen?Inogen revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Inogen?Current revenue multiple of Inogen is 0.2x.
What is the current EBITDA of Inogen?Inogen's last 12 months EBITDA is $3M.
What is Inogen's EBITDA margin?Inogen's last 12 months EBITDA margin is 1%.
What is the current EV/EBITDA multiple of Inogen?Current EBITDA multiple of Inogen is 29.0x.
What is the current FCF of Inogen?Inogen's last 12 months FCF is ($19M).
What is Inogen's FCF margin?Inogen's last 12 months FCF margin is (5%).
What is the current EV/FCF multiple of Inogen?Current FCF multiple of Inogen is (4.4x).
How many companies Inogen has acquired to date?As of July 2026, Inogen has acquired 1 company.
What was the largest acquisition by Inogen?$32M acquisition of PhysioAssist on 13th July 2023 was the largest M&A Inogen has done to date.
What companies Inogen acquired?Inogen acquired PhysioAssist.
In how many companies Inogen has invested to date?Inogen hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Inogen

Lists including Inogen

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial